Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05396885 · ClinicalTrials.gov registry record · Phase 2
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
A Phase 2 study of Multiple Myeloma, sponsored by Kite, A Gilead Company.
- Active
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 18
- Study locations
NCT05396885: Active Phase 2 study of Multiple Myeloma, sponsored by Kite, A Gilead Company.
NCT05396885 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Kite, A Gilead Company. The registered enrollment target is 136 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% lower). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05396885, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Kite, A Gilead Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 18
- Study locations
Study Summary
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
Primary Outcome
ORR Per International Myeloma Working Group (IMWG) criteria, as assessed by an independent review committee (IRC)
Conditions Studied
Interventions
- BIOLOGICAL anitocabtagene-autoleucel
Study Locations (18)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Texas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Wisconsin
- University of Wisconsin Clinical Science Center - Madison
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Arizona
- HonorHealth Cancer Transplant Institute - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT05396885 still lists
NCT05396885 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which anitocabtagene-autoleucel is the first listed.
NCT05396885 lists 18 locations in 15 states (Massachusetts, Texas, Wisconsin).
Frequently Asked Questions
What is clinical trial NCT05396885 about?
NCT05396885 is a clinical study titled "Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)". A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
What is the current status of trial NCT05396885?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2022-07-15. Estimated completion is 2026-12.
What conditions does trial NCT05396885 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05396885?
The interventions under investigation include: anitocabtagene-autoleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT05396885?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05396885 being conducted?
This trial has 18 study locations across Arizona, Arkansas, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05396885's enrollment target sits among peer trials
136 141st of 438 higher than 298 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI